Alan Boobis

List of Publications by Year
in descending order

273 papers	15,427 citations	13099 68 h-index	22832 112 g-index
293 all docs	293 docs citations	293 times ranked	12954 citing authors

#	Article	IF	Citations
1	Methyl-tert-butyl ether (MTBE): integration of rat and mouse carcinogenicity data with mode of action and human and rodent bioassay dosimetry and toxicokinetics indicates MTBE is not a plausible human carcinogen. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2022, 25, 135-161.	6.5	2
2	A new approach to the classification of carcinogenicity. Archives of Toxicology, 2022, 96, 2419-2428.	4.2	5
3	Characterising vaping products in the United Kingdom: an analysis of Tobacco Products Directive notification data. Addiction, 2021, 116, 2521-2528.	3.3	4
4	Opportunities and challenges related to saturation of toxicokinetic processes: Implications for risk assessment. Regulatory Toxicology and Pharmacology, 2021, 127, 105070.	2.7	10
5	Use of the kinetically-derived maximum dose: Opportunities for delivering 3Rs benefits. Regulatory Toxicology and Pharmacology, 2020, 116, 104734.	2.7	7
6	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity: how to evaluate the risk of the S-EDCs?. Archives of Toxicology, 2020, 94, 2549-2557.	4.2	11
7	Hazard identification, classification, and risk assessment of carcinogens: too much or too little? â€“ Report of an ECETOC workshop. Critical Reviews in Toxicology, 2020, 50, 72-95.	3.9	15
8	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2020, 83, 485-494.	2.3	8
9	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Environmental Toxicology and Pharmacology, 2020, 78, 103396.	4.0	1
10	An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. Regulatory Toxicology and Pharmacology, 2020, 112, 104592.	2.7	108
11	Relevance of mouse lung tumors to human risk assessment. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2020, 23, 214-241.	6.5	19
12	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Toxicology in Vitro, 2020, 67, 104861.	2.4	5
13	Characterizing the coverage of critical effects relevant in the safety evaluation of food additives by AOPs. Archives of Toxicology, 2019, 93, 2115-2125.	4.2	17
14	Value and limitation ofin vitrobioassays to support the application of the threshold of toxicological concern to prioritise unidentified chemicals in food contact materials. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2019, 36, 1903-1936.	2.3	21
15	Chemical carcinogenicity revisited 2: Current knowledge of carcinogenesis shows that categorization as a carcinogen or non-carcinogen is not scientifically credible. Regulatory Toxicology and Pharmacology, 2019, 103, 124-129.	2.7	47
16	A mode-of-action ontology model for safety evaluation of chemicals: Outcome of a series of workshops on repeated dose toxicity. Toxicology in Vitro, 2019, 59, 44-50.	2.4	19
17	Harmonized methodology to assess chronic dietary exposure to residues from compounds used as pesticide and veterinary drug. Critical Reviews in Toxicology, 2019, 49, 1-10.	3.9	8
18	Risk Benefit Assessment of foods: Key findings from an international workshop. Food Research International, 2019, 116, 859-869.	6.2	29

#	Article	IF	Citations
19	Chemical carcinogenicity revisited 3: Risk assessment of carcinogenic potential based on the current state of knowledge of carcinogenesis in humans. Regulatory Toxicology and Pharmacology, 2019, 103, 100-105.	2.7	64
20	Chemical carcinogenicity revisited 1: A unified theory of carcinogenicity based on contemporary knowledge. Regulatory Toxicology and Pharmacology, 2019, 103, 86-92.	2.7	56
21	Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: a perspective. Toxicology Research, 2018, 7, 347-357.	2.1	70
22	Building a developmental toxicity ontology. Birth Defects Research, 2018, 110, 502-518.	1.5	24
23	Benchmark dose (BMD) modeling: current practice, issues, and challenges. Critical Reviews in Toxicology, 2018, 48, 387-415.	3.9	131
24	Human relevance of rodent liver tumors: Key insights from a Toxicology Forum workshop on nongenotoxic modes of action. Regulatory Toxicology and Pharmacology, 2018, 92, 1-7.	2.7	50
25	Obfuscating transparency?. Regulatory Toxicology and Pharmacology, 2018, 97, A1-A3.	2.7	2
26	Response to Loomis etÂal Comment on Boobis etÂal. Regulatory Toxicology and Pharmacology, 2017, 88, 358-359.	2.7	2
27	IARC use of oxidative stress as key mode of action characteristic for facilitating cancer classification: Glyphosate case example illustrating a lack of robustness in interpretative implementation. Regulatory Toxicology and Pharmacology, 2017, 86, 157-166.	2.7	23
28	Origin of the TTC values for compounds that are genotoxic and/or carcinogenic and an approach for their re-evaluation. Critical Reviews in Toxicology, 2017, 47, 710-732.	3.9	33
29	Improving selection of markers in nutrition research: evaluation of the criteria proposed by the ILSI Europe Marker Validation Initiative. Nutrition Research Reviews, 2017, 30, 73-81.	4.1	3
30	Thresholds of Toxicological Concern for cosmetics-related substances: New database, thresholds, and enrichment of chemical space. Food and Chemical Toxicology, 2017, 109, 170-193.	3.6	108
31	â€œThe dose makes the poisonâ€• Key implications for mode of action (mechanistic) research in a 21st century toxicology paradigm. Current Opinion in Toxicology, 2017, 3, 87-91.	5.0	25
32	Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; increasing utility and facilitating regulatory acceptance. Critical Reviews in Toxicology, 2017, 47, 733-753.	3.9	54
33	How well can carcinogenicity be predicted by high throughput â€œcharacteristics of carcinogensâ€• mechanistic data?. Regulatory Toxicology and Pharmacology, 2017, 90, 185-196.	2.7	37
34	Towards establishing a consistent set of criteria to assess the use of non-animal methods in regulatory decision making. Toxicology Letters, 2017, 280, S16.	0.8	0
35	Characterizing chronic and acute health risks of residues of veterinary drugs in food: latest methodological developments by the joint FAO/WHO expert committee on food additives. Critical Reviews in Toxicology, 2017, 47, 889-903.	3.9	28
36	A framework for cumulative risk assessment in the 21st century. Critical Reviews in Toxicology, 2017, 47, 85-97.	3.9	47

#	Article	IF	Citations
37	Scientific principles for the identification of endocrine-disrupting chemicals: a consensus statement. Archives of Toxicology, 2017, 91, 1001-1006.	4.2	118
38	Problem formulation for risk assessment of combined exposures to chemicals and other stressors in humans. Critical Reviews in Toxicology, 2016, 46, 835-844.	3.9	32
39	Utility of AOPs/MOAs in assessing the effects of endocrine disruptors. Toxicology Letters, 2016, 258, S28.	0.8	0
40	Upholding science in health, safety and environmental risk assessments and regulations. Toxicology, 2016, 371, 12-16.	4.2	7
41	Allowing pseudoscience into EU risk assessment processes is eroding public trust in science experts and in science as a whole: The bigger picture. Chemico-Biological Interactions, 2016, 257, 1-3.	4.0	11
42	Classification schemes for carcinogenicity based on hazard-identification have become outmoded and serve neither science nor society. Regulatory Toxicology and Pharmacology, 2016, 82, 158-166.	2.7	61
43	Considering new methodologies in strategies for safety assessment of foods and food ingredients. Food and Chemical Toxicology, 2016, 91, 19-35.	3.6	54
44	Effects of mid-respiratory chain inhibition on mitochondrial function in vitro and in vivo. Toxicology Research, 2016, 5, 136-150.	2.1	9
45	Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer. Oncotarget, 2016, 7, 44505-44521.	1.8	22
46	Towards microbial fermentation metabolites as markers for health benefits of prebiotics. Nutrition Research Reviews, 2015, 28, 42-66.	4.1	251
47	Adverse Outcome Pathways can drive nonâ€animal approaches for safety assessment. Journal of Applied Toxicology, 2015, 35, 971-975.	2.8	82
48	PGC-1Î± controls mitochondrial biogenesis and dynamics in lead-induced neurotoxicity. Aging, 2015, 7, 629-643.	3.1	87
49	The role of hazard- and risk-based approaches in ensuring food safety. Trends in Food Science and Technology, 2015, 46, 176-188.	15.1	76
50	Human health screening level risk assessments of tertiary-butyl acetate (TBAC): Calculated acute and chronic reference concentration (RfC) and Hazard Quotient (HQ) values based on toxicity and exposure scenario evaluations. Critical Reviews in Toxicology, 2015, 45, 142-171.	3.9	6
51	E2F1-Mediated FOS Induction in Arsenic Trioxideâ€“Induced Cellular Transformation: Effects of Global H3K9 Hypoacetylation and Promoter-Specific Hyperacetylation in Vitro. Environmental Health Perspectives, 2015, 123, 484-492.	6.0	11
52	Risk assessments for chronic exposure of children and prospective parents to ethylbenzene (CAS No.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.9	7
53	Target organ profiles in toxicity studies supporting human dosing: Does severity progress with longer duration of exposure?. Regulatory Toxicology and Pharmacology, 2015, 73, 737-746.	2.7	15
54	Risk assessment in the 21st century: Roadmap and matrix. Critical Reviews in Toxicology, 2014, 44, 6-16.	3.9	98

#	Article	IF	Citations
55	Instruments for Assessing Risk of Bias and Other Methodological Criteria of Animal Studies: Omission of Well-Established Methods. Environmental Health Perspectives, 2014, 122, A66-7.	6.0	1
56	A 21st century roadmap for human health risk assessment. Critical Reviews in Toxicology, 2014, 44, 1-5.	3.9	88
57	The use of mode of action information in risk assessment: Quantitative key events/dose-response framework for modeling the dose-response for key events. Critical Reviews in Toxicology, 2014, 44, 17-43.	3.9	65
58	New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. Journal of Applied Toxicology, 2014, 34, 1-18.	2.8	223
59	Establishing the level of safety concern for chemicals in food without the need for toxicity testing. Regulatory Toxicology and Pharmacology, 2014, 68, 275-296.	2.7	44
60	Systems Toxicology: From Basic Research to Risk Assessment. Chemical Research in Toxicology, 2014, 27, 314-329.	3.3	287
61	Selection of appropriate tumour data sets for Benchmark Dose Modelling (BMD) and derivation of a Margin of Exposure (MoE) for substances that are genotoxic and carcinogenic: Considerations of biological relevance of tumour type, data quality and uncertainty assessment. Food and Chemical Toxicology, 2014, 70, 264-289.	3.6	28
62	Conclusions and discussion. Toxicology Letters, 2014, 229, S11.	0.8	0
63	Interpretation of margins of exposure for genotoxic carcinogens. Toxicology Letters, 2014, 229, S105.	0.8	0
64	A framework for fit-for-purpose dose response assessment. Regulatory Toxicology and Pharmacology, 2013, 66, 234-240.	2.7	14
65	Reevaluate Pesticides for Food Security and Safety. Science, 2013, 341, 717-718.	12.6	132
66	An F1-Extended One-Generation Reproductive Toxicity Study in Crl:CD(SD) Rats With 2,4-Dichlorophenoxyacetic Acid. Toxicological Sciences, 2013, 136, 527-547.	3.1	36
67	Interpretation of the margin of exposure for genotoxic carcinogens â€“ Elicitation of expert knowledge about the form of the dose response curve at human relevant exposures. Food and Chemical Toxicology, 2013, 57, 106-118.	3.6	11
68	Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans. Food and Chemical Toxicology, 2013, 60, 550-562.	3.6	25
69	Critical appraisal of the assessment of benefits and risks for foods, â€˜BRAFO Consensus Working Groupâ€™. Food and Chemical Toxicology, 2013, 55, 659-675.	3.6	33
70	Life-Stage-, Sex-, and Dose-Dependent Dietary Toxicokinetics and Relationship to Toxicity of 2,4-Dichlorophenoxyacetic Acid (2,4-D) in Rats: Implications for Toxicity Test Dose Selection, Design, and Interpretation. Toxicological Sciences, 2013, 136, 294-307.	3.1	32
71	Elucidation of Toxicity Pathways in Lung Epithelial Cells Induced by Silicon Dioxide Nanoparticles. PLoS ONE, 2013, 8, e72363.	2.5	39
72	Risk assessment of contaminants in food and feed. EFSA Journal, 2012, 10, s1004.	1.8	49

#	Article	IF	Citations
73	BRAFO tiered approach for benefitâ€“risk assessment of foods. Food and Chemical Toxicology, 2012, 50, S684-S698.	3.6	57
74	Use of toxicokinetics to support chemical evaluation: Informing high dose selection and study interpretation. Regulatory Toxicology and Pharmacology, 2012, 62, 241-247.	2.7	42
75	Assessment of diurnal systemic dose of agrochemicals in regulatory toxicity testing â€“ An integrated approach without additional animal use. Regulatory Toxicology and Pharmacology, 2012, 63, 321-332.	2.7	49
76	Using mode of action information to improve regulatory decision-making: An ECETOC/ILSI RF/HESI workshop overview. Critical Reviews in Toxicology, 2011, 41, 175-186.	3.9	49
77	Application of the TTC concept to unknown substances found in analysis of foods. Food and Chemical Toxicology, 2011, 49, 1643-1660.	3.6	46
78	Managing the challenge of chemically reactive metabolites in drug development. Nature Reviews Drug Discovery, 2011, 10, 292-306.	46.4	382
79	Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework. Regulatory Toxicology and Pharmacology, 2011, 60, S1-S14.	2.7	252
80	Alternative (non-animal) methods for cosmetics testing: current status and future prospectsâ€”2010. Archives of Toxicology, 2011, 85, 367-485.	4.2	488
81	A proposed framework for assessing risk from less-than-lifetime exposures to carcinogens. Critical Reviews in Toxicology, 2011, 41, 507-544.	3.9	41
82	Critical analysis of literature on low-dose synergy for use in screening chemical mixtures for risk assessment. Critical Reviews in Toxicology, 2011, 41, 369-383.	3.9	132
83	Mode of Action Considerations in the Quantitative Assessment of Tumour Responses in the Liver. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 173-179.	2.5	10
84	Authors response to Huff et al., â€œClarifying carcinogenicity of ethylbenzeneâ€• Regulatory Toxicology and Pharmacology, 2010, 58, 170-172.	2.7	0
85	Guidance for the classification of carcinogens under the Globally Harmonised System of Classification and Labelling of Chemicals (GHS). Critical Reviews in Toxicology, 2010, 40, 245-285.	3.9	21
86	Application of Key Events Analysis to Chemical Carcinogens and Noncarcinogens. Critical Reviews in Food Science and Nutrition, 2009, 49, 690-707.	10.3	94
87	Fate and occurrence of alkylphenolic compounds in sewage sludges determined by liquid chromatography tandem mass spectrometry. Environmental Technology (United Kingdom), 2009, 30, 1415-1424.	2.2	9
88	A Data-Based Assessment of Alternative Strategies for Identification of Potential Human Cancer Hazards. Toxicologic Pathology, 2009, 37, 714-732.	1.8	43
89	The Key Events Dose-Response Framework: A Cross-Disciplinary Mode-of-Action Based Approach to Examining Dose-Response and Thresholds. Critical Reviews in Food Science and Nutrition, 2009, 49, 682-689.	10.3	90
90	Increased Expression of Histone Proteins during Estrogen-Mediated Cell Proliferation. Environmental Health Perspectives, 2009, 117, 928-934.	6.0	26

#	Article	IF	Citations
91	The significance of sample mass in the analysis of steroid estrogens in sewage sludges and the derivation of partition coefficients in wastewaters. Journal of Chromatography A, 2009, 1216, 4923-4926.	3.7	19
92	Influence of Operating Parameters on the Biodegradation of Steroid Estrogens and Nonylphenolic Compounds during Biological Wastewater Treatment Processes. Environmental Science & Technology, 2009, 43, 6646-6654.	10.0	89
93	Effects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models. Expert Opinion on Therapeutic Targets, 2009, 13, 867-887.	3.4	8
94	Critical analysis of literature on low dose synergy for use of TTC in screening chemical mixtures for risk assessment. Toxicology Letters, 2009, 189, S51.	0.8	2
95	Risk assessment of mixtures of mutagenic and carcinogenic chemicals: A regulatory perspective from the UK. Toxicology Letters, 2009, 189, S271.	0.8	0
96	Drug interactions. Drug Metabolism Reviews, 2009, 41, 486-527.	3.6	45
97	Identification of estrogenâ€responsive proteins in MCFâ€7 human breast cancer cells using labelâ€free quantitative proteomics. Proteomics, 2008, 8, 1987-2005.	2.2	24
98	Cumulative risk assessment of pesticide residues in food. Toxicology Letters, 2008, 180, 137-150.	0.8	237
99	Proteomic analysis of human breast cell lines using SELDI-TOF MS shows that mixtures of estrogenic compounds exhibit simple similar action (concentration additivity). Toxicology Letters, 2008, 181, 93-103.	0.8	9
100	TREATMENT AND REMOVAL STRATEGIES FOR ESTROGENS FROM WASTEWATER. Environmental Technology (United Kingdom), 2008, 29, 245-267.	2.2	128
101	A sensitive and robust method for the determination of alkylphenol polyethoxylates and their carboxylic acids and their transformation in a trickling filter wastewater treatment plant. Chemosphere, 2008, 73, 551-556.	8.2	26
102	IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans. Critical Reviews in Toxicology, 2008, 38, 87-96.	3.9	352
103	Local Kinetics and Dynamics of Xenobiotics. Critical Reviews in Toxicology, 2008, 38, 697-720.	3.9	38
104	Re: Guyton, Kathryn Z., Barone, Stanley, Jr., Brown, Rebecca C., Euling, Susan Y., Jinot, Jennifer, Makris, Susan (2008). Mode of Action Frameworks: A Critical Analysis.Journal of Toxicology and Environmental Health, Part B, 11(1): 16â€“31. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2008, 11, 681-685.	6.5	10
105	Testicular Dysgenesis Syndrome and the Estrogen Hypothesis: A Quantitative Meta-Analysis. Environmental Health Perspectives, 2008, 116, 149-157.	6.0	99
106	Testicular dysgenesis syndrome and the estrogen hypothesis: a quantitative meta-analysis. Ciencia E Saude Coletiva, 2008, 13, 1601-1618.	0.5	12
107	Defective Spermatogenesis: Martin et al. Respond. Environmental Health Perspectives, 2008, 116, .	6.0	0
108	Scaling Factors for the Extrapolation of In Vivo Metabolic Drug Clearance From In Vitro Data: Reaching a Consensus on Values of Human Micro-somal Protein and Hepatocellularity Per Gram of Liver. Current Drug Metabolism, 2007, 8, 33-45.	1.2	398

#	Article	IF	Citations
109	Human Health and Endocrine Disruption: A Simple Multicriteria Framework for the Qualitative Assessment of End Point Specific Risks in a Context of Scientific Uncertainty. Toxicological Sciences, 2007, 98, 332-347.	3.1	29
110	Searching for novel biomarkers of centrally and peripehrally-acting neurotoxicants, using surface-enhanced laser desorption/ionisation-time-of-flight mass spectrometry (SELDI-TOF MS). Food and Chemical Toxicology, 2007, 45, 2126-2137.	3.6	4
111	Classification of carcinogens under the GHS: Proposals for guidance. Toxicology Letters, 2007, 172, S22.	0.8	0
112	Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda. ATLA Alternatives To Laboratory Animals, 2007, 35, 661-671.	1.0	59
113	Determination of steroid estrogens in wastewater by high performance liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography A, 2007, 1173, 81-87.	3.7	100
114	C-Terminal antibodies (CTAbs): A simple and broadly applicable approach for the rapid generation of protein-specific antibodies with predefined specificity. Proteomics, 2007, 7, 1364-1372.	2.2	9
115	Expression of Cytochromes P450 3A and P-Glycoprotein in Human Large Intestinse in Paired Tumour and Normal Samples. Basic and Clinical Pharmacology and Toxicology, 2007, 100, 240-248.	2.5	29
116	Risk Assessment of Dietary Supplements. Novartis Foundation Symposium, 2007, 282, 3-28.	1.1	4
117	IPCS Framework for Analyzing the Relevance of a Cancer Mode of Action for Humans. Critical Reviews in Toxicology, 2006, 36, 781-792.	3.9	416
118	A Tiered Approach to Systemic Toxicity Testing for Agricultural Chemical Safety Assessment. Critical Reviews in Toxicology, 2006, 36, 37-68.	3.9	92
119	Agricultural Chemical Safety Assessment: A Multisector Approach to the Modernization of Human Safety Requirements. Critical Reviews in Toxicology, 2006, 36, 1-7.	3.9	57
120	Assessment of uncertainty in a probabilistic model of consumer exposure to pesticide residues in food. Food Additives and Contaminants, 2006, 23, 601-615.	2.0	14
121	OMICS research adds substantially to the safety assessment of chemicals: The case against. Toxicology Letters, 2006, 164, S28.	0.8	0
122	Dose-dependent transitions in mechanisms of toxicity: Concluding remarks. Toxicology Letters, 2006, 164, S37-S38.	0.8	0
123	Use of protein profiles to characterise concentrationâ€“effect curves of mixtures of estrogenic compounds in human breast cell lines. Toxicology Letters, 2006, 164, S165-S166.	0.8	4
124	IPCS framework for analysing the relevance of a cancer mode of action for humans. Toxicology Letters, 2006, 164, S254-S255.	0.8	7
125	Determination of a Human Hepatic Microsomal Scaling Factor for Predicting in Vivo Drug Clearance. Pharmaceutical Research, 2006, 23, 533-539.	3.5	67
126	Meta-analysis of Studies of Alcohol and Breast Cancer with Consideration of the Methodological Issues. Cancer Causes and Control, 2006, 17, 759-770.	1.8	201

#	Article	IF	Citations
127	Strategies to assess systemic exposure of chemicals in subchronic/chronic diet and drinking water studies. Toxicology and Applied Pharmacology, 2006, 211, 245-260.	2.8	60
128	Evidence for genotoxicity of pesticides in pesticide applicators: a review. Mutagenesis, 2006, 21, 93-103.	2.6	113
129	4-Aminobiphenyl and DNA Reactivity: Case Study Within the Context of the 2006 IPCS Human Relevance Framework for Analysis of a Cancer Mode of Action for Humans. Critical Reviews in Toxicology, 2006, 36, 803-819.	3.9	43
130	Thiazopyr and Thyroid Disruption: Case Study Within the Context of the 2006 IPCS Human Relevance Framework for Analysis of a Cancer Mode of Action. Critical Reviews in Toxicology, 2006, 36, 793-801.	3.9	57
131	Mode of Action in Relevance of Rodent Liver Tumors to Human Cancer Risk. Toxicological Sciences, 2006, 89, 51-56.	3.1	246
132	CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenetics and Genomics, 2005, 15, 625-631.	1.5	87
133	Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: consequences for risk from exposure to diazinon. Pharmacogenetics and Genomics, 2005, 15, 51-60.	1.5	35
134	Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. British Journal of Clinical Pharmacology, 2005, 60, 107-112.	2.4	200
135	Positron emission tomography in the quantification of cellular and biochemical responses to intrapulmonary particulates. Toxicology and Applied Pharmacology, 2005, 207, 230-236.	2.8	11
136	An approach to investigating the importance of high potency polycyclic aromatic hydrocarbons (PAHs) in the induction of lung cancer by air pollution. Food and Chemical Toxicology, 2005, 43, 1103-1116.	3.6	146
137	Molecular approaches to the identification of biomarkers of exposure and effectâ€"report of an expert meeting organized by COST Action B15. Toxicology Letters, 2005, 156, 227-240.	0.8	26
138	Cruciferous vegetable consumption alters the metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in humans. Carcinogenesis, 2004, 25, 1659-1669.	2.8	87
139	Urinary N2-(2'-deoxyguanosin-8-yl)PhIP as a biomarker for PhIP exposure. Carcinogenesis, 2004, 25, 1053-1062.	2.8	8
140	Dose-dependent transitions in mechanisms of toxicity. Toxicology and Applied Pharmacology, 2004, 201, 203-225.	2.8	162
141	Dose-dependent transitions in mechanisms of toxicity: case studies. Toxicology and Applied Pharmacology, 2004, 201, 226-294.	2.8	164
142	Approaches to carcinogenic risk assessment for polycyclic aromatic hydrocarbons: a UK perspective. Regulatory Toxicology and Pharmacology, 2004, 40, 54-66.	2.7	117
143	Differential expression of cytochrome P450 enzymes in cultured and intact foetal rat ventral mesencephalon. Journal of Neural Transmission, 2003, 110, 1091-1101.	2.8	4
144	Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. British Journal of Clinical Pharmacology, 2003, 55, 68-76.	2.4	152

#	Article	IF	Citations
145	Expression of CYP3A4 in human breast tumour and non-tumour tissues. Cancer Letters, 2003, 202, 17-23.	7.2	34
146	COMPARATIVE ANALYSIS OF CYP3A EXPRESSION IN HUMAN LIVER SUGGESTS ONLY A MINOR ROLE FOR CYP3A5 IN DRUG METABOLISM. Drug Metabolism and Disposition, 2003, 31, 755-761.	3.3	213
147	Risk characterisation of chemicals in food and diet. Food and Chemical Toxicology, 2003, 41, 1211-1271.	3.6	167
148	Immunohistochemical demonstration of the expression of CYP2E1 in human breast tumour and non-tumour tissues. Cancer Letters, 2003, 196, 153-159.	7.2	30
149	Adduction of the Chloroform Metabolite Phosgene to Lysine Residues of Human Histone H2B. Chemical Research in Toxicology, 2003, 16, 266-275.	3.3	25
150	COMPARATIVE STUDIES ON THE CYTOCHROME P450-ASSOCIATED METABOLISM AND INTERACTION POTENTIAL OF SELEGILINE BETWEEN HUMAN LIVER-DERIVED IN VITRO SYSTEMS. Drug Metabolism and Disposition, 2003, 31, 1093-1102.	3.3	77
151	Induction of Cytochrome P450 Enzymes in Cultured Precision-Cut Human Liver Slices. Drug Metabolism and Disposition, 2003, 31, 282-288.	3.3	89
152	A STRATEGY FOR INVESTIGATING THE CYP SUPERFAMILY USING TARGETED ANTIBODIES IS A PARADIGM FOR FUNCTIONAL GENOMIC STUDIES. Drug Metabolism and Disposition, 2003, 31, 1476-1480.	3.3	13
153	Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for Pre-phase I positron emission tomography studies in cancer patients. British Journal of Cancer, 2002, 86, 1052-1056.	6.4	20
154	The mutational signature of alpha-hydroxytamoxifen at Hprt locus in Chinese hamster cells. Carcinogenesis, 2002, 23, 1947-1952.	2.8	2
155	Current knowledge and recent developments in consumer exposure assessment of pesticides: A UK perspective. Food Additives and Contaminants, 2002, 19, 837-852.	2.0	22
156	Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica, 2002, 32, 505-520.	1.1	340
157	Expression of P450 enzymes in rat whole skin and cultured epidermal keratinocytes. Biochemical and Biophysical Research Communications, 2002, 297, 65-70.	2.1	31
158	Methods of in vitro toxicology. Food and Chemical Toxicology, 2002, 40, 193-236.	3.6	367
159	Kinetics of Lung Macrophages Monitored in Vivo Following Particulate Challenge in Rabbits. Toxicology and Applied Pharmacology, 2002, 183, 46-54.	2.8	32
160	Cytochrome P450 3A Expression in the Human Fetal Liver: Evidence that CYP3A5 Is Expressed in Only a Limited Number of Fetal Livers. Neonatology, 2001, 80, 193-201.	2.0	66
161	COST B15: modelling in drug development. British Journal of Clinical Pharmacology, 2001, 52, 118-119.	2.4	1
162	Diazinon Is Activated by CYP2C19 in Human Liver. Toxicology and Applied Pharmacology, 2001, 177, 68-76.	2.8	95

#	Article	IF	Citations
163	In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report. European Journal of Clinical Pharmacology, 2001, 57, 621-629.	1.9	55
164	Assessment of P450 induction in the marmoset monkey using targeted anti-peptide antibodies. BBA - Proteins and Proteomics, 2001, 1546, 143-155.	2.1	18
165	Carbamazepine: a 'blind' assessment of CYP-associated metabolism and interactions in human liver-derivedin vitrosystems. Xenobiotica, 2001, 31, 321-343.	1.1	57
166	Inhibition of human CYP1A2 activityin vitroby methylxanthines: potent competitive inhibition by 8-phenyltheophylline. Xenobiotica, 2001, 31, 135-151.	1.1	11
167	Effect of cruciferous vegetable consumption on heterocyclic aromatic amine metabolism in man. Carcinogenesis, 2001, 22, 1413-1420.	2.8	89
168	Adducts of the Chloroform Metabolite Phosgene. Advances in Experimental Medicine and Biology, 2001, 500, 129-132.	1.6	4
169	Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. , 2000, 86, 610-616.		86
170	Expression and distribution of CYP2C enzymes in rat basal ganglia. Synapse, 2000, 38, 392-402.	1.2	15
171	Mass spectrometric detection and measurement of N2-(2â€²-deoxyguanosin-8-yl)PhIP adducts in DNA. Biomedical Applications, 2000, 744, 55-64.	1.7	21
172	The mutagenicity of benzo[a]pyrene in mouse small intestine. Carcinogenesis, 1999, 20, 109-114.	2.8	31
173	Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochemical Pharmacology, 1999, 58, 787-796.	4.4	206
174	Expression and localisation of CYP2D enzymes in rat basal ganglia. Brain Research, 1999, 822, 175-191.	2.2	26
175	Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics and Genomics, 1999, 9, 357-366.	5.7	49
176	Development of a Comprehensive Panel of Antibodies against the Major Xenobiotic Metabolising Forms of Cytochrome P450 in Humans. Biochemical Pharmacology, 1998, 56, 377-387.	4.4	122
177	Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase. Neuroscience, 1998, 86, 511-519.	2.3	71
178	Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide. Respiratory Medicine, 1998, 92, 2-6.	2.9	40
179	Pulmonary Fibrosis Correlates with Duration of Tissue Neutrophil Activation. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 620-628.	5.6	100
180	Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. Xenobiotica, 1998, 28, 493-506.	1.1	20

#	Article	IF	Citations
181	Genetic analysis of PHIP intestinal mutations in MutaTMMouse. Mutagenesis, 1998, 13, 601-605.	2.6	38
182	Analysis of the N-(deoxyguanosin-8-yl) adduct of the food derived carcinogen PhIP using capillary electrophoresis. Biochemical Society Transactions, 1997, 25, 27S-27S.	3.4	0
183	Evidence for nitric oxide participation in down-regulation of CYP2B1/2 gene expression at the pretranslational level. Toxicology Letters, 1997, 90, 207-216.	0.8	34
184	Specific inhibition of human CYPLA2 using a targeted antibody. Biochemical Pharmacology, 1997, 54, 189-197.	4.4	6
185	Expression and localization of CYP3A4 and CYP3A5 in human lung.. American Journal of Respiratory Cell and Molecular Biology, 1997, 16, 242-249.	2.9	138
186	Assessing human risk to heterocyclic amines. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 376, 53-60.	1.0	36
187	The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. European Journal of Clinical Pharmacology, 1997, 52, 311-315.	1.9	69
188	Expression and inducibility of P450 enzymes during liver ontogeny. , 1997, 39, 424-435.		81
189	Expression of xenobiotic-metabolizing cytochrome P450 Forms in human full-term placenta. Biochemical Pharmacology, 1996, 51, 403-411.	4.4	196
190	Interindividual variability in metabolic activation in humans in vivo. Environmental Toxicology and Pharmacology, 1996, 2, 161-163.	4.0	2
191	Brain Cytochrome P450 in the Rat. Biochemical Society Transactions, 1996, 24, 52S-52S.	3.4	3
192	Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera. Brain Research, 1996, 743, 324-328.	2.2	50
193	Dissecting the function of cytochrome P450. British Journal of Clinical Pharmacology, 1996, 42, 81-89.	2.4	19
194	Developmental changes in hepatic activation of 2-amino-3, 8-dimethylimidazo[4, 5-f]quinoxaline in rabbit. Carcinogenesis, 1996, 17, 555-558.	2.8	3
195	ACCELERATED PAPER: Mutational spectra of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) at the Chinese hamster hprt locus. Carcinogenesis, 1996, 17, 617-624.	2.8	72
196	Enzymic and Interindividual Differences in the Human Metabolism of Heterocyclic Amines. Archives of Toxicology Supplement, 1996, 18, 286-302.	0.7	17
197	Exposure to and activation of dietary heterocyclic amines in humans. Critical Reviews in Oncology/Hematology, 1995, 21, 19-31.	4.4	16
198	Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes. Biochemical Pharmacology, 1995, 49, 39-47.	4.4	51

#	Article	IF	Citations
199	Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochemical Pharmacology, 1995, 50, 2047-2056.	4.4	94
200	Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis, 1994, 15, 829-836.	2.8	131
201	Preface. Toxicology in Vitro, 1994, 8, 505.	2.4	2
202	The role of CYP1A enzymes in murine activation of the cooked food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Biochemical Society Transactions, 1994, 22, 128S-128S.	3.4	0
203	The 'Register of Toxicologists'. Human and Experimental Toxicology, 1994, 13, 377-380.	2.2	4
204	An inhibitory monoclonal anti-protein antibody and an anti-peptide antibody share an epitope on rat cytochrome enzymes CYP1A1 and CYP1A2. BBA - Proteins and Proteomics, 1993, 1161, 38-46.	2.1	9
205	Identification of the epitope of an anti-peptide antibody which binds to CYP1A2 in many species including man. Biochemical Pharmacology, 1993, 46, 213-220.	4.4	30
206	Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis, 1993, 14, 585-592.	2.8	68
207	N-Hydroxy-MeIQx is the major microsomal oxidation product of the dietary carcinogen MeIQx with human liver. Carcinogenesis, 1992, 13, 2221-2226.	2.8	51
208	Molecular basis for differences in susceptibility to toxicants: introduction. Toxicology Letters, 1992, 64-65, 109-113.	0.8	4
209	Identification of the epitope of a monoclonal antibody which binds to several cytochromes P450 in the CYP1A subfamily. Biochemical Pharmacology, 1992, 43, 1737-1746.	4.4	9
210	Expression of CYP2E1 during human fetal development: methylation of the CYP2E1 gene in human fetal and adult liver samples. Biochemical Pharmacology, 1992, 43, 1876-1879.	4.4	57
211	Paracetamol toxicity in hamster isolated hepatocytes: The increase in cytosolic calcium accompanies, rather than precedes, loss of viability. Archives of Toxicology, 1992, 66, 408-412.	4.2	16
212	Orientation of cytochromes P450 in the endoplasmic reticulum. Biochemistry, 1991, 30, 71-76.	2.5	76
213	[22] Antipeptide antibodies in studies of cytochromes P450IA. Methods in Enzymology, 1991, 206, 220-233.	1.0	25
214	Combined assay for phenacetin and paracetamol in plasma using capillary column gas chromatographyâ€"negative-ion mass spectrometry. Biomedical Applications, 1991, 568, 341-350.	1.7	24
215	Rapid analysis for metabolites of 11C-labelled drugs: fate of [11C]-S-4-(tert.-butylamino-2-hydroxypropoxy)-benzimidazol-2-one in the dog. Biomedical Applications, 1991, 570, 361-370.	1.7	19
216	Mechanisms of cell death. Archives of Toxicology, 1991, 65, 437-444.	4.2	170

#	Article	IF	Citations
217	Assay of caffeine metabolism in vitro by human liver microsomes using radio-high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 1990, 8, 783-787.	2.8	7
218	Mechanisms of cell toxicity. Current Opinion in Cell Biology, 1990, 2, 231-237.	5.4	19
219	Ontogeny of expression, distribution and inducibility of cytochromes P450IA1 and IA2 In hepatic and exirahepatic tissues of the rat. European Journal of Pharmacology, 1990, 183, 1502.	3.5	1
220	Evidence for a direct role of intracellular calcium in paracetamol toxicity. Biochemical Pharmacology, 1990, 39, 1277-1281.	4.4	50
221	High affinity phenacetin O-deethylase is catalysed specifically by cytochrome P450d (P450IA2) in the liver of the rat. Biochemical Pharmacology, 1990, 39, 489-498.	4.4	52
222	The inducibility and catalytic activity of cytochromes P450c (P450IA1) and P450d (P450IA2) in rat tissues. Biochemical Pharmacology, 1990, 39, 499-506.	4.4	76
223	Rapid tolerance to the hypotensive effects of glyceryl trinitrate in the rat: prevention by Nâ€¤acetylâ€‹<scp>l</scp>â€•but not Nâ€¤acetylâ€‹<scp>d</scp>â€¤cysteine. British Journal of Pharmacology, 1990, 99, 825-829.	7.4	28
224	The Effects of Trimethadione and Its Metabolite on Human Liver Debrisoquine 4-Hydroxylase Activity In Vitro. The Showa University Journal of Medical Sciences, 1990, 2, 27-30.	0.1	0
225	Cross-reaction of antibodies to coupling groups used in the production of anti-peptide antibodies. Journal of Immunological Methods, 1989, 117, 215-220.	1.4	28
226	Identification and location of .alpha.-helices in mammalian cytochromes P450. Biochemistry, 1989, 28, 3762-3770.	2.5	88
227	The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochemical Pharmacology, 1989, 38, 2795-2799.	4.4	116
228	Immunohistochemical localization of cytochrome P450b/e in hepatic and extrahepatic tissues of the rat. Biochemical Pharmacology, 1989, 38, 3305-3322.	4.4	55
229	Antibodies against rat cytochrome P-450d: comparison of the purified protein and a synthetic peptide as immunogens. Biochemical Society Transactions, 1989, 17, 535-536.	3.4	0
230	3,8-Dimethyl-2-nitro-imidazo[4,5-f]quinoxaline(Nitro-MeIQx) is a potent direct-acting mutagen. Biochemical Society Transactions, 1989, 17, 540-541.	3.4	0
231	Activation of the food carcinogen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline by hepatocytes. Biochemical Society Transactions, 1989, 17, 734-735.	3.4	2
232	Species differences in specificity of hydrocarbon-inducible forms of cytochrome P-450. Biochemical Society Transactions, 1989, 17, 1021-1022.	3.4	1
233	Identification of surface regions of cytochromes P-450 using anti-peptide antibodies. Biochemical Society Transactions, 1989, 17, 1022-1023.	3.4	2
234	Ontogeny of expression, inducibility and distribution of cytochromes P-450 forms 4 and 6 in rabbit liver. Biochemical Society Transactions, 1989, 17, 1023-1024.	3.4	3

#	Article	IF	Citations
235	Determination of theN-acetyl metabolites of 4,4â€²-methylene dianiline and 4,4â€²-methylene-bis(2-chloroaniline) in urine. Biological Mass Spectrometry, 1988, 17, 161-167.	0.5	49
236	Antibodies to a synthetic peptide that react specifically with a common surface region on two hydrocarbon-inducible isoenzymes of cytochrome P-450 in the rat. Biochemical Pharmacology, 1988, 37, 3735-3741.	4.4	40
237	Hepatotoxicity of carbon tetrachloride: protection by pretreatment of mice with polyriboinosinic acid polyribocytidylic acid. Biochemical Society Transactions, 1988, 16, 632-633.	3.4	0
238	Cytoprotective effects of 16,16-dimethyl prostaglandin E2 on paracetamol toxicity in isolated hepatocytes. Biochemical Society Transactions, 1988, 16, 641-642.	3.4	2
239	Immunohistochemical localization of cytochrome P-450 b/e in hepatic and extrahepatic rat tissues. Biochemical Society Transactions, 1988, 16, 642-643.	3.4	2
240	Species differences in the hepatotoxicity of paracetamol are due to differences in the rate of conversion to its cytotoxic metabolite. Biochemical Pharmacology, 1987, 36, 1041-1052.	4.4	84
241	Bufuralol 1'-hydroxylase activity of the rat. Biochemical Pharmacology, 1986, 35, 2961-2965.	4.4	32
242	Immunocytochemical localization of cytochrome P-450 in hepatic and extra-hepatic tissues of the rat with a monoclonal antibody against cytochrome P-450 c. Biochemical Pharmacology, 1986, 35, 4543-4554.	4.4	110
243	Is the activation of aflatoxin B1 catalysed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man?. Archives of Toxicology, 1986, 58, 165-170.	4.2	6
244	The metabolic activation of 4,4â€²-methylene-bis-(2-chlorobenzeneamine) to a bacterial mutagen by hepatic postmitochondrial supernatant from human and other species. Environmental Mutagenesis, 1985, 7, 501-509.	1.4	6
245	Polymorphic metabolism of the carcinogen 2-acetylaminofluorene in human liver microsomes. Carcinogenesis, 1985, 6, 1721-1724.	2.8	35
246	Antipyrine elimination in patients with obstructive jaundice: A predictor of outcome. American Journal of Surgery, 1985, 149, 140-143.	1.8	23
247	Genetic polymorphism in drug oxidation: In vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1â€²-hydroxylase activities. Biochemical Pharmacology, 1985, 34, 65-71.	4.4	66
248	A monoclonal antibody raised to rat liver cytochrome P-448 (form c) which recognises an epitope common to many other forms of cytochrome P-450. Biochemical Pharmacology, 1985, 34, 1671-1681.	4.4	25
249	Species differences in the hepatic formation of green pigments following the administration of norethindrone. Biochemical Pharmacology, 1984, 33, 459-464.	4.4	5
250	Multiple forms of human cytochrome P-450. Biochemical Society Transactions, 1984, 12, 78-80.	3.4	6
251	Interindividual Differences in Monooxygenase Activities of Human Liver. , 1984, , 109-153.		1
252	Effect of rifampicin and isoniazid on vitamin D metabolism. Clinical Pharmacology and Therapeutics, 1982, 32, 525-530.	4.7	93

#	Article	IF	Citations
253	Immunopurification of cytochrome P-448 from microsomal fractions of rabbit liver with retention of metabolic activity. Biochemical Pharmacology, 1982, 31, 1815-1817.	4.4	16
254	Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractions. Biochemical Pharmacology, 1981, 30, 2451-2456.	4.4	80
255	The selective activation of cytochrome P-450 dependent microsomal hydroxylases in human and rat liver microsomes. Biochemical Pharmacology, 1981, 30, 1702-1703.	4.4	19
256	Differential induction of antipyrine metabolism by rifampicin. European Journal of Clinical Pharmacology, 1981, 21, 155-160.	1.9	74
257	Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity. Clinical Pharmacology and Therapeutics, 1981, 30, 363-367.	4.7	66
258	Paracetamol oxidation: synthesis and reactivity of N-acetyl-p-benzoquinoneimine. Tetrahedron Letters, 1980, 21, 4947-4950.	1.4	57
259	Stereoselective excretion of (3-methoxy-4-sulphooxyphenyl)ethylene glycol (MHPG sulphate) in the dog. Naunyn-Schmiedeberg's Archives of Pharmacology, 1980, 314, 89-96.	3.0	6
260	DNA Binding of Benzo[a]pyrene Metabolites. Pharmacology, 1980, 20, 137-148.	2.2	14
261	Catecholamine Turnover in Essential Hypertension. Clinical and Experimental Hypertension, 1980, 2, 395-408.	1.3	7
262	DRUG OXIDATION IN ASIAN VEGETARIANS. Lancet, The, 1980, 316, 151.	13.7	13
263	Genetic Differences in the Metabolic Activation of Benzo[a]Pyrene in Mice. Pharmacology, 1979, 18, 281-293.	2.2	32
264	A Rapid Sensitive Assay for Glutathione S-Epoxidetransferase Activity: Species Differences in the Activity of the Hepatic Enzyme. Biochemical Society Transactions, 1979, 7, 1060-1061.	3.4	8
265	Effects of microsomal enzyme inducers in vivo and inhibitors in vitro on the covalent binding of benzo[a]pyrene metabolites to DNA catalyzed by liver microsomes from genetically responsive and nonresponsive mice. Biochemical Pharmacology, 1979, 28, 111-121.	4.4	29
266	Species differences in the substrate specificity of hepatic cytochrome P-448 From polycyclic hydrocarbon-treated animals. Biochemical Pharmacology, 1979, 28, 217-226.	4.4	82
267	Genetic differences in the metabolism of carcinogens and in the binding of benzo[a]pyrene metabolites to DNA. Advances in Enzyme Regulation, 1977, 15, 339-362.	2.6	9
268	Induction of aryl hydrocarbon (benzo[a]pyrene) hydroxylase and 2-acetylaminofluorene N-hydroxylase by polycyclic hydrocarbons in regenerating liver from inbred strains of mice. Biochemical Pharmacology, 1977, 26, 1501-1505.	4.4	5
269	Differential induction of murine Ah locus-associated monooxygenase activities in rabbit liver and kidney. Biochemical Pharmacology, 1975, 24, 2111-2116.	4.4	42
270	Ethanol protection against hemicholinium toxicity in mice. Biochemical Pharmacology, 1975, 24, 485-488.	4.4	5

#	Article	IF	Citations
271	The effect of pretreating rats with 3-methylcholanthrene upon the enhancement of microsomal aniline hydroxylation by acetone and other agents. Biochemical Pharmacology, 1975, 24, 424-426.	4.4	12
272	Effect of washing the hepatic microsomal fraction in sucrose solutions and in sucrose solution containing edta upon the metabolism of foreign compounds. Biochemical Pharmacology, 1975, 24, 1771-1776.	4.4	20
273	The effects of catecholamines upon the metabolism of foreign compounds and upon the distribution of perfusate in the isolated liver of the rat. Biochemical Pharmacology, 1974, 23, 3377-3384.	4.4	12